<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383760</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00173</org_study_id>
    <secondary_id>PHL-049</secondary_id>
    <secondary_id>CDR0000502291</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <nct_id>NCT00383760</nct_id>
  </id_info>
  <brief_title>Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients</brief_title>
  <official_title>A Phase II Study of the Halichondrin B Analog E7389 as Second Line Therapy for Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well E7389 works as second-line therapy in treating
      patients with locally advanced, unresectable, or metastatic pancreatic cancer. Drugs used in
      chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To determine the objective response (complete and partial) to E7389 in patients with
      locally advanced, unresectable, or metastatic pancreatic adenocarcinoma that progressed after
      prior gemcitabine hydrochloride-based therapy.

      SECONDARY OBJECTIVE:

      I. To determine the antitumor activity of E7389, in terms of median survival, 1-year survival
      rate, response or stable disease duration, toxicity, and time to disease progression, in
      these patients.

      OUTLINE: This is an open-label, multicenter study. Patients receive eribulin mesylate IV on
      days 1 and 8. Treatment repeats every 3 weeks in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, all patients are followed at 4 weeks. Patients with
      complete response, partial response, or stable disease are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response (Complete and Partial) Evaluated Using RECIST Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable Disease Rate, Evaluated Using RECIST Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival Time</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 6 months</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Progression</measure>
    <time_frame>Duration of time from start of treatment until the criteria for progression are met, assessed up to 3 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>At 6 months</time_frame>
    <description>Estimated using the Kaplan-Meier method.
Median time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>At 1 year</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>All patients will be evaluable for toxicity from the time of their first treatment with E7389.</time_frame>
    <description>Types of Gr 3 or greater adverse events that are atleast possibly related to study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Stable Disease Rate</measure>
    <time_frame>Upto 3 years</time_frame>
    <description>Objective stable disease rate Using RECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (eribulin mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive E7389 IV on days 1 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eribulin mesylate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (eribulin mesylate)</arm_group_label>
    <other_name>B1939</other_name>
    <other_name>E7389</other_name>
    <other_name>ER-086526</other_name>
    <other_name>halichrondrin B analog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed pancreatic carcinoma (locally advanced,
             unresectable or metastatic)

          -  measurable disease (at least 1 lesion accurately measured in at least 1 dimension
             (longest diameter as &gt;20mm with conventional techniques or &gt;10mm with spiral CT scan)

          -  &gt;=4 weeks from any major surgery

          -  Up to 1 prior line of gemcitabine based systemic therapy (single agent/combination
             therapy) for locally advanced/metastatic disease with evidence of disease progression.
             Prior therapy with inhibitors of angiogenesis and/or the epidermal growth factor
             receptor permitted. Last chemotherapy dose &gt;=4 weeks prior to randomization.

          -  May have received prior 5FU (+/- folinic acid)/gemcitabine given concurrently with
             radiation as a &quot;radiation sensitizer&quot;. Last chemotherapy dose &gt;=4 weeks prior to
             randomization.

          -  Prior radiation treatment &gt;=4 weeks prior to randomization

          -  Age &gt;18 years.

          -  Life expectancy &gt;=3 months

          -  ECOG&lt; 2(Karnofsky-60%)

          -  leukocytes&gt;3,000/mcL

          -  absolute neutrophil count&gt;1,500/mcL

          -  platelets&gt;100,000/mcL

          -  total bilirubin &lt; 1.5 UNL

          -  AST/ALTâ‰¤2.5x institutional ULN

          -  creatinine within institution limits OR creatinine clearance&gt;60mL/min/1.73m2 for
             patients with creatinine levels above institution limits

          -  concurrent use of inhibitors/inducers of CYP3A4 are prohibited during the study
             treatment period

          -  effects of E7389 on developing human fetus are unknown. Women of childbearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation

          -  Ability to understand/willingness to sign written informed consent

        Exclusion Criteria:

          -  chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
             prior to entering study or those who have not recovered from adverse events due to
             agents administered more than 4 weeks earlier

          -  May not be receiving other investigational agents

          -  Known brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to E7389

          -  Uncontrolled intercurrent illness including but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study

          -  Pregnant women excluded because E7389 is an antitubulin agent with the potential for
             teratogenic/abortifacient effects

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             potential for p PK interactions with E7389

          -  Other active malignancies in past 5 years except for cervical carcinoma in situ and
             non-melanomatous skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Moore</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>April 18, 2014</results_first_submitted>
  <results_first_submitted_qc>October 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>E7389</title>
          <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Eribulin Mesylate)</title>
          <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: 1.4mg/m2 given IV weekly day 1,8 every 21 days (1 cycle).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="34" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response (Complete and Partial) Evaluated Using RECIST Criteria</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response (Complete and Partial) Evaluated Using RECIST Criteria</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stable Disease Rate, Evaluated Using RECIST Criteria</title>
        <description>Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Stable Disease Rate, Evaluated Using RECIST Criteria</title>
          <description>Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="15" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival Time</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival Time</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="25" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>At 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Disease Progression</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>Duration of time from start of treatment until the criteria for progression are met, assessed up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Disease Progression</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Estimated using the Kaplan-Meier method.
Median time to progression</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Estimated using the Kaplan-Meier method.
Median time to progression</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.2" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>At 1 year</time_frame>
        <population>Time to progression at 1 year not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Eribulin Mesylate)</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <population>Time to progression at 1 year not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Duration</title>
        <time_frame>From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>E7389</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Response Duration</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Types of Gr 3 or greater adverse events that are atleast possibly related to study drug</description>
        <time_frame>All patients will be evaluable for toxicity from the time of their first treatment with E7389.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E7389</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Types of Gr 3 or greater adverse events that are atleast possibly related to study drug</description>
          <units>Types of adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Stable Disease Rate</title>
        <description>Objective stable disease rate Using RECIST</description>
        <time_frame>Upto 3 years</time_frame>
        <population>Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>E7389</title>
            <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Stable Disease Rate</title>
          <description>Objective stable disease rate Using RECIST</description>
          <population>Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Eribulin Mesylate)</title>
          <description>Patients receive E7389 IV on days 1 and 8.
eribulin mesylate: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Malcolm Moore</name_or_title>
      <organization>Princess Margaret Cancer Centre</organization>
      <phone>416-945-2263</phone>
      <email>malcolm.moore@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

